Over-expression of the dominant-negative isoform of Ikaros confers resistance to dexamethasone-induced and anti-IgM-induced apoptosis

Nobuo Sezaki, Fumihiko Ishimaru, Minoru Takata, Takayuki Tabayashi, Koichi Nakase, Teruhiko Kozuka, Keiko Fujii, Hiroyuki Nakayama, Takanori Teshima, Mine Harada, Mitsune Tanimoto

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

In previous studies, we demonstrated an over-expression of the dominant-negative isoform of the transcription factor Ikaros, Ik-6, in patients with B-cell malignancies, including blast crisis of chronic myelogenous leukaemia and acute lymphoblastic leukaemia. To investigate the consequence of over-expression of Ik-6 in B cells, we constructed Ik-6 transfectants of the FDH-1 and Ramos cell lines. FDH-1, which was established from a patient with early pre-B acute lymphoblastic leukaemia, undergoes apoptosis with dexamethasone treatment, whereas Ramos undergoes apoptosis following anti-IgM antibody treatment. Compared with the wild type, the over-expression of Ik-6 rendered the FDH-1 and Ramos transfectants resistant to dexamethasone-induced and anti-IgM-induced apoptosis respectively. An immunoblotting study demonstrated bcl-2 upregulation in anti-IgM-induced Ramos Ik-6 transfectants, but not in FDH-1 Ik-6 transfectants. Further investigations of the mechanism of leukaemogenesis associated with the over-expression of Ik-6 are warranted.

Original languageEnglish
Pages (from-to)165-169
Number of pages5
JournalBritish Journal of Haematology
Volume121
Issue number1
DOIs
Publication statusPublished - Apr 2003

Fingerprint

Dexamethasone
Protein Isoforms
Apoptosis
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Ikaros Transcription Factor
B-Lymphocytes
Blast Crisis
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Immunoblotting
Anti-Idiotypic Antibodies
Up-Regulation
Cell Line
Therapeutics
anti-IgM
Neoplasms

Keywords

  • Anti-IgM
  • Apoptosis
  • Dexamethasone
  • Dominant-negative isoform
  • Ikaros

ASJC Scopus subject areas

  • Hematology

Cite this

Over-expression of the dominant-negative isoform of Ikaros confers resistance to dexamethasone-induced and anti-IgM-induced apoptosis. / Sezaki, Nobuo; Ishimaru, Fumihiko; Takata, Minoru; Tabayashi, Takayuki; Nakase, Koichi; Kozuka, Teruhiko; Fujii, Keiko; Nakayama, Hiroyuki; Teshima, Takanori; Harada, Mine; Tanimoto, Mitsune.

In: British Journal of Haematology, Vol. 121, No. 1, 04.2003, p. 165-169.

Research output: Contribution to journalArticle

Sezaki, N, Ishimaru, F, Takata, M, Tabayashi, T, Nakase, K, Kozuka, T, Fujii, K, Nakayama, H, Teshima, T, Harada, M & Tanimoto, M 2003, 'Over-expression of the dominant-negative isoform of Ikaros confers resistance to dexamethasone-induced and anti-IgM-induced apoptosis', British Journal of Haematology, vol. 121, no. 1, pp. 165-169. https://doi.org/10.1046/j.1365-2141.2003.04263.x
Sezaki, Nobuo ; Ishimaru, Fumihiko ; Takata, Minoru ; Tabayashi, Takayuki ; Nakase, Koichi ; Kozuka, Teruhiko ; Fujii, Keiko ; Nakayama, Hiroyuki ; Teshima, Takanori ; Harada, Mine ; Tanimoto, Mitsune. / Over-expression of the dominant-negative isoform of Ikaros confers resistance to dexamethasone-induced and anti-IgM-induced apoptosis. In: British Journal of Haematology. 2003 ; Vol. 121, No. 1. pp. 165-169.
@article{20809952a6b34948a564d704af93b419,
title = "Over-expression of the dominant-negative isoform of Ikaros confers resistance to dexamethasone-induced and anti-IgM-induced apoptosis",
abstract = "In previous studies, we demonstrated an over-expression of the dominant-negative isoform of the transcription factor Ikaros, Ik-6, in patients with B-cell malignancies, including blast crisis of chronic myelogenous leukaemia and acute lymphoblastic leukaemia. To investigate the consequence of over-expression of Ik-6 in B cells, we constructed Ik-6 transfectants of the FDH-1 and Ramos cell lines. FDH-1, which was established from a patient with early pre-B acute lymphoblastic leukaemia, undergoes apoptosis with dexamethasone treatment, whereas Ramos undergoes apoptosis following anti-IgM antibody treatment. Compared with the wild type, the over-expression of Ik-6 rendered the FDH-1 and Ramos transfectants resistant to dexamethasone-induced and anti-IgM-induced apoptosis respectively. An immunoblotting study demonstrated bcl-2 upregulation in anti-IgM-induced Ramos Ik-6 transfectants, but not in FDH-1 Ik-6 transfectants. Further investigations of the mechanism of leukaemogenesis associated with the over-expression of Ik-6 are warranted.",
keywords = "Anti-IgM, Apoptosis, Dexamethasone, Dominant-negative isoform, Ikaros",
author = "Nobuo Sezaki and Fumihiko Ishimaru and Minoru Takata and Takayuki Tabayashi and Koichi Nakase and Teruhiko Kozuka and Keiko Fujii and Hiroyuki Nakayama and Takanori Teshima and Mine Harada and Mitsune Tanimoto",
year = "2003",
month = "4",
doi = "10.1046/j.1365-2141.2003.04263.x",
language = "English",
volume = "121",
pages = "165--169",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Over-expression of the dominant-negative isoform of Ikaros confers resistance to dexamethasone-induced and anti-IgM-induced apoptosis

AU - Sezaki, Nobuo

AU - Ishimaru, Fumihiko

AU - Takata, Minoru

AU - Tabayashi, Takayuki

AU - Nakase, Koichi

AU - Kozuka, Teruhiko

AU - Fujii, Keiko

AU - Nakayama, Hiroyuki

AU - Teshima, Takanori

AU - Harada, Mine

AU - Tanimoto, Mitsune

PY - 2003/4

Y1 - 2003/4

N2 - In previous studies, we demonstrated an over-expression of the dominant-negative isoform of the transcription factor Ikaros, Ik-6, in patients with B-cell malignancies, including blast crisis of chronic myelogenous leukaemia and acute lymphoblastic leukaemia. To investigate the consequence of over-expression of Ik-6 in B cells, we constructed Ik-6 transfectants of the FDH-1 and Ramos cell lines. FDH-1, which was established from a patient with early pre-B acute lymphoblastic leukaemia, undergoes apoptosis with dexamethasone treatment, whereas Ramos undergoes apoptosis following anti-IgM antibody treatment. Compared with the wild type, the over-expression of Ik-6 rendered the FDH-1 and Ramos transfectants resistant to dexamethasone-induced and anti-IgM-induced apoptosis respectively. An immunoblotting study demonstrated bcl-2 upregulation in anti-IgM-induced Ramos Ik-6 transfectants, but not in FDH-1 Ik-6 transfectants. Further investigations of the mechanism of leukaemogenesis associated with the over-expression of Ik-6 are warranted.

AB - In previous studies, we demonstrated an over-expression of the dominant-negative isoform of the transcription factor Ikaros, Ik-6, in patients with B-cell malignancies, including blast crisis of chronic myelogenous leukaemia and acute lymphoblastic leukaemia. To investigate the consequence of over-expression of Ik-6 in B cells, we constructed Ik-6 transfectants of the FDH-1 and Ramos cell lines. FDH-1, which was established from a patient with early pre-B acute lymphoblastic leukaemia, undergoes apoptosis with dexamethasone treatment, whereas Ramos undergoes apoptosis following anti-IgM antibody treatment. Compared with the wild type, the over-expression of Ik-6 rendered the FDH-1 and Ramos transfectants resistant to dexamethasone-induced and anti-IgM-induced apoptosis respectively. An immunoblotting study demonstrated bcl-2 upregulation in anti-IgM-induced Ramos Ik-6 transfectants, but not in FDH-1 Ik-6 transfectants. Further investigations of the mechanism of leukaemogenesis associated with the over-expression of Ik-6 are warranted.

KW - Anti-IgM

KW - Apoptosis

KW - Dexamethasone

KW - Dominant-negative isoform

KW - Ikaros

UR - http://www.scopus.com/inward/record.url?scp=0037392235&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037392235&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2141.2003.04263.x

DO - 10.1046/j.1365-2141.2003.04263.x

M3 - Article

C2 - 12670348

AN - SCOPUS:0037392235

VL - 121

SP - 165

EP - 169

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 1

ER -